Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Samotolisib + Enzalutamide in mCRPC
NCT02407054Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2015
- Primary completion
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of samotolisib in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Eli Lilly and Company. Started Apr 2015; status: completed.
02
Drugs
samotolisib
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT02407054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02407054.